Citius pharmaceuticals announces publication in frontiers of immunology of positive results from solid tumor study of lymphir™ in combination with checkpoint inhibitor

Preclinical study demonstrates that adding lymphir to anti-pd-1 treatment augments anti-tumor activity and improves overall survival compared to monotherapy alone by transiently depleting tregs in the tumor microenvironment cranford, n.j. , oct. 31, 2023 /prnewswire/ -- citius pharmaceuticals, inc. ("citius" or the "company") (nasdaq: ctxr) today announced that preclinical research on lymphir ("denileukin diftitox" or "e7777") was published today in frontiers in immunology 1, a leading peer-reviewed journal in the immunology field.
CTXR Ratings Summary
CTXR Quant Ranking